Patient Focused.
Medical Conferences
-
Southeastern Society Of Plastic Surgeons Meeting
June 15 - 18, 2025
Read More » -
UCSF Biennial PRS Symposium
June 20 - 21, 2025
Read More » -
Children's Craniofacial Association Annual Retreat
June 26 - 29, 2025
Read More » -
AOSSM
July 10 - 12, 2025
Read More » -
Premier Breakthroughs
July 15 - 17, 2025
Read More »
New CMS coverage guidelines include AmnioBand® Membrane and AlloPatch® Pliable.
MTF Biologics is dedicated to offering the highest quality tissue solutions backed by Level 1 clinical evidence*. As the only company offering a placental and dermal solution, we are proud to be 1 of 9 companies included under the new Medicare LCD.
* MTF Biologics data on file
The two MTF Biologics tissues to be covered
Covered for both Diabetic Foot Ulcers and Venous Leg Ulcers
A minimally processed placental allograft which retains the structural properties of the extracellular matrix. It's aseptically processed, and ready right off the shelf.
Covered for Diabetic Foot Ulcers
A minimally processed human reticular dermis that serves as a framework to support cellular repopulation and vascularization. It's aseptically processed, and ready right off the shelf.
- 80% complete wound closure at 12 weeks.³
New Medicare LCD will limit the number of skin substitutes covered:
“Our inclusion on this exclusive list of covered tissues highlights our ability to deliver trusted tissues that meet the needs of clinicians and patients alike.”
– Joe Yaccarino, President & CEO of MTF Biologics
Aseptic Processing
MTF Biologics’ process balances safety with quality by ensuring the preservation of inherent biological properties of the tissue. Our processing avoids the use of harsh chemicals and terminal radiation which can damage tissue integrity and lead to suboptimal clinical outcomes. Aseptic processing employed by MTF Biologics maintains the most natural tissue, offering exceptional biocompatibility with the recipient host tissue.
Founded by Surgeons to Serve Surgeons
We’ve taken wound care outcomes into new territory. Our multiple, peer-reviewed, level 1 clinical outcomes studies are proof that we develop wound care treatment approaches that work. Our advancements—in shapes, sizes and forms appropriate for many different clinical circumstances—can restore native tissue in acute and chronic wounds in less time at less cost. The progress we continue to make not only moves science forward, it helps to heal and save lives.
If you are a U.S. healthcare professional and need more information, please complete our Healthcare Professional Form.
Centurion Therapeutics is the official wound care partner of MTF Biologics and provides marketing and support to various surgical specialties with their network of independent representatives around the US.
Contact Centurion Therapeutics, our exclusive partner, for additional information or to request your local representative.
Contact NowInquiries
Interested in learning more? Contact a representative today.
¹DiDomenico LA, Orgill DP, Galiano RD, Serena TE, Carter MJ, Kaufman JP, Young NJ, Jacobs AM, Zelen CM. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers: A prospective, randomised, multi-centre clinical trial in 80 patients. International Wound Journal. 2018; 1-8.
²Glat P, Orgill DP, Galiano R, Armstrong D, Serena T, DiDomenico LA, Kaufman J, Carter MJ, Jacobs AM, Zelen CM. Placental Membrane Provides Improved Healing Efficacy and Lower Cost Versus a Tissue-Engineered Human Skin in the Treatment of Diabetic Foot Ulcerations. Plast Reconstr Surg Glob Open. 2019 Aug 30;7(8):e2371. doi: 10.1097/GOX.0000000000002371. PMID: 31592387; PMCID: PMC6756673.
³Serena TE, Orgill DP, Armstrong D, Galiano RD, Glat P, Carter MJ, Kaufman JP, Li W, Zelen CM. A Multicenter, Randomized, Controlled, Clinical Trial Evaluating Dehydrated Human Amniotic Membrane in the Treatment of Venous Leg Ulcers. Plastic Reconstructive Surgery. 2022.
⁴Zelen CM, Orgill DP, Serena T, Galiano R, Carter MJ, DiDomenico LA, Keller J, Kaufman J, Li WW. A prospective, randomized, controlled, multicenter clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017 Apr;14(2):307-315. doi: 10.1111/iwj.12600. Epub 2016 Apr 12. PMID: 27073000; PMCID: PMC7949710.
